✦ LIBER ✦

Tocilizumab in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-modifying Antirheumatic Drugs or Tumor Necrosis Factor Inhibitors: Subanalysis of Spanish Results of an Open-label Study Close to Clinical Practice

✍ Scribed by Álvaro-Gracia, José M.; Fernández-Nebro, Antonio; García-López, Alicia; Guzmán, Manuel; Blanco, Francisco J.; Navarro, Francisco J.; Bustabad, Sagrario; Armendáriz, Yolanda; Román-Ivorra, José A.

Book ID: 122172242
Publisher: Elsevier Science
Year: 2014
Tongue: Spanish
Weight: 544 KB
Volume: 10
Category: Article
ISSN: 2173-5743
DOI: 10.1016/j.reumae.2013.12.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of tocilizumab in patients with

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

✍ Yazici, Y.; Curtis, J. R.; Ince, A.; Baraf, H.; Malamet, R. L.; Teng, L. L.; Kav 📂 Article 📅 2011 🏛 BMJ Publishing Group 🌐 English ⚖ 301 KB

Indirect comparisons of the efficacy of

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

✍ Salliot, C.; Finckh, A.; Katchamart, W.; Lu, Y.; Sun, Y.; Bombardier, C.; Keysto 📂 Article 📅 2010 🏛 BMJ Publishing Group 🌐 English ⚖ 299 KB

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 4 views